New UK Market Surveillance Levy Could Cost Medtech Companies Millions Each Year
This article was originally published in Clinica
Executive Summary
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) wants to charge an annual fee to manufacturers to pay for its market surveillance activities, but is expected to issue a 12-week public consultation first. The exact level of fee is not yet known but is expected to be in the region of 0.12% of turnover, Mike Kreuzer, regulatory director of the Association of British Healthcare Industries told delegates at the Bristows/ABHI medical device meeting in London on April 21.
You may also be interested in...
Medtech Worried After UK HTA Body Moots Pharma Guidance Fees
The UK health technology assessment body, NICE, has received its first reactions from a medtech industry association to proposals to raise fees from its program of pharma guidance. If, when or how quickly the medtech sector is fully impacted is a matter of concern across the SME-based industry.
EU Regulatory Experts Support Notified Bodies, But Argue For Greater Consistency
Notified bodies have been a pivotal part of the EU medtech regulatory system since it was first launched in the 1990s. Where might they fit within a new medtech regulatory governance structure? Panelists on a recent vodcast grappled with the question.
First Public Discussion On How EU Medtech Regulatory Governance Structure May Evolve
Does the EU need a medtech agency for the first time in its history? Nothing can or should be decided too quickly but five high-profile experts broadly agreed that change is now critical.